SCHEMBL3494572

SCHEMBL3494572

Cc1ccc2c(C(=O)N3CCC4(CC3)CC(=O)c3cc(C#N)ccc3S4)c(N)sc2n1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ACACA Q13085 8/20 0.33
ACACB O00763 6/20 0.33
ALOX15 P16050 2/20 0.32
USP2 O75604 2/20 0.32
MAPK1 P28482 2/20 0.32
HIF1A Q16665 1/20 0.32
HSP90AB1 P08238 1/20 0.31
IKBKB O14920 1/20 0.31
LIMK1 P53667 1/20 0.31
MAPT P10636 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
KDM1A O60341 1/20 0.31
FASN P49327 2/20 0.30
USP28 Q96RU2 1/20 0.30
USP25 Q9UHP3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490756 0.89 NPC1 (0.35) SMN1; SMN2KDM4EALDH1A1ACACAACACB
SCHEMBL13636854 0.89 ACACB (0.35) SMN1; SMN2KDM4EALDH1A1ACACAACACB
SCHEMBL3491729 0.88 USP2 (0.33) SMN1; SMN2ACACAUSP2USP28USP25
SCHEMBL3494981 0.88 ACACB (0.35) SMN1; SMN2ALDH1A1ACACAACACBIKBKB
SCHEMBL3492698 0.88 ACACB (0.34) SMN1; SMN2KDM4EALDH1A1ACACAACACB
SCHEMBL3493749 0.87 SLC6A7 (0.32) SMN1; SMN2ALDH1A1ACACAACACBMAPK1
SCHEMBL3493700 0.87 ALDH1A1 (0.40) SMN1; SMN2KDM4EALDH1A1ACACAACACB
SCHEMBL3493044 0.86 ACACB (0.48) ALDH1A1ACACAACACBMAPK1
SCHEMBL3493048 0.86 ACACB (0.48) ALDH1A1ACACAACACBMAPK1
SCHEMBL3492562 0.86 MAPT (0.36) KDM4EALDH1A1ACACAACACBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
EP-2123652-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113418-A1 HETEROCYCLIC COMPOUND ACACA, ACAT1, CPT1B SMN1; SMN2 889/4885KDM4E 1143/4885ALDH1A1 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.